Considering that obesity is a multifactorial disease, it needs multimodal treatment
Semaglutide is prescribed for: Weight loss in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) Weight loss in adult patients with an initial body mass index (BMI) of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (hypertension, type 2 diabetes mellitus, or dyslipidemia) Weight loss in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity) Reducing the risk of major adverse cardiovascular events (non-fatal myocardial infarction, CV death, or non-fatal stroke) in adults with cardiovascular disease and either obesity or overweight Treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, with moderate to advanced liver fibrosis (stages F2 to F3 fibrosis) in adults Patients taking semaglutide for any of these conditions, especially weight loss, are typically suggested to maintain a low-carb and low-fat diet
The trials produced signals consistent with the mechanism (the peptide does what its pharmacology predicts it would do), but the effect sizes were not large enough to support a successful path to drug approval as a standalone obesity treatment
Free B12 then binds to R-proteins secreted by salivary glands
Applications include investigating type 2 diabetes prevention, insulin resistance mechanisms, and novel therapeutic approaches for metabolic dysfunction through enzymatic pathway modulation
Current investigations explore relationships between NNMT inhibition and: Obesity research Healthy aging Cellular metabolism Mitochondrial biology Energy homeostasis Fat metabolism Glucose regulation Nutrient utilization Researchers also investigate whether NNMT inhibition influences broader biological pathways connected with longevity research and metabolic resilience
